Department of Neurosurgery, Seikeikai General Hospital, Osaka, Japan.
Department of Neurosurgery, Nara Medical University, Nara, Japan.
World Neurosurg. 2020 Aug;140:e266-e272. doi: 10.1016/j.wneu.2020.05.014. Epub 2020 May 11.
A 9-French (Fr) sheath is routinely used during mechanical thrombectomy (MT) for treating acute ischemic stroke (AIS). However, the use of a large sheath is a risk factor for access site complications (ASCs). Previous studies focused on preventing intracranial complications, and only a few have explored ASCs. We investigated the technical feasibility and efficacy of a sheathless procedure for AIS (SPAIS) that uses a 9-Fr balloon-guiding catheter as a guiding sheath to reduce the sheath size and prevent ASCs during MT.
We retrospectively analyzed the data of 133 patients who underwent MT at our center. Patients treated between January 2015 and August 2017 received conventional treatment (C) using a 9-Fr sheath, and SPAIS was attempted in patients treated between September 2017 and October 2019. We first assessed the technical feasibility of SPAIS, and subsequently compared the incidence of ASCs between the SPAIS and C groups. Routine postsurgical ASC assessments using duplex ultrasonography were performed during the post-MT bed-rest period.
The technical success rate of SPAIS was 97.6% (81 of 83 patients). The incidence of ASCs was significantly lower in the SPAIS group (2 of 81, 2.5%) than in the C group (7 of 52, 13.4%) (P < 0.05). Moreover, developed pseudoaneurysms in the SPAIS group showed significantly faster hemostasis than those in the C group (mean 20 minutes vs. 32 minutes; P < 0.05).
SPAIS is a feasible technique that effectively reduces MT-associated ASCs; thus, this approach should be adopted to improve patient outcomes.
在机械取栓(MT)治疗急性缺血性脑卒中(AIS)中,常规使用 9Fr 鞘管。然而,大鞘管的使用是血管入路并发症(ASCs)的危险因素。先前的研究侧重于预防颅内并发症,只有少数研究探讨了 ASCs。我们研究了鞘内无鞘(SPAIS)程序治疗 AIS 的技术可行性和疗效,该程序使用 9Fr 球囊引导导管作为引导鞘管,以减小鞘管尺寸并预防 MT 期间的 ASCs。
我们回顾性分析了在我院接受 MT 的 133 例患者的数据。2015 年 1 月至 2017 年 8 月期间接受常规治疗(C)的患者使用 9Fr 鞘管,2017 年 9 月至 2019 年 10 月期间尝试 SPAIS。我们首先评估 SPAIS 的技术可行性,然后比较 SPAIS 组和 C 组 ASC 的发生率。MT 后卧床休息期间,常规进行术后 ASC 超声检查。
SPAIS 的技术成功率为 97.6%(81/83 例)。SPAIS 组的 ASC 发生率明显低于 C 组(2/81,2.5%)(P<0.05)。此外,SPAIS 组的新发假性动脉瘤的止血速度明显快于 C 组(平均 20 分钟 vs. 32 分钟;P<0.05)。
SPAIS 是一种可行的技术,可有效降低 MT 相关 ASC 的发生率;因此,应采用这种方法来改善患者的预后。